HLA-B and familial pancreatic carcinoma: Our results demonstrate that the combination of HLA-B*15:01 and DRB1*15:01 is over-represented significantly in Japanese patients with advanced pancreatic cancer who developed ILD after the treatment with gemcitabine plus erlotinib.